Agalimmune licenses KODE Biotech's Function-Spacer-Lipid cell modificator technology

15 June 2015

Personalized oncology specialist biopharma company Agalimmune has licensed KODE Biotech’s Function-Spacer-Lipid (FSL) cell surface membrane modification technology.

It will be incorporated by Agalimmune into its novel cancer immunotherapy molecules. KODE may receive up to $31 million in development and sales milestones, plus royalties on net sales, while Agalimmune has exclusive rights to use of the technology in the field of intratumoral injection for cancer treatment. Prior to this agreement, KODE technology has been extensively validated by Agalimmune prior to in-licensing. It has been shown to be effective for treatment of primary and secondary tumors in animal models.

Agalimmune injects synthetic animal-antigen mimetics, which incorporate the FSL constructs, into primary tumors. As the immune system naturally rejects animal tissue, it attacks the modified tumor.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK